Unknown Attendee

Good afternoon, and welcome to everyone that's joining us today, and a big thank you from the Shield Therapeutics team. We will be going through the Q1 2026 trading presentation today. [Operator Instructions] The company might not be in a position to answer any -- all questions today. However, we will review all questions and where appropriate, share responses following today's presentation. The webinar today is being recorded and will be published on the Shield Therapeutics' Investor website.

I'd like to now hand over to the Shield Therapeutics CEO, Anders; CFO, Santosh; and CCO, Andy.

Anders Lundstrom
CEO & Executive Director

Thank you, Polly, and we'll go to the slides. Good afternoon, good morning, everybody. So we're here to review our first quarter trading update, and we can go to the next slide immediately, Polly actually. So you introduced us all know so you know who's on the call. This one before that, which is our disclaimer. You go back one, please. Actually, the disclaimer still is there. Thank you very much. So this is our disclaimer.

And also, in addition, this presentation will be posted on our website later this week. And as you heard initially, we have received a number of questions. Thank you so much for that. And those questions we will not have time to answer today, we will post in writing. We'll answer in writing and post that as well. So we'll answer as many questions as we can during this broadcast.

So we can take the next slide, please. So this is our executive team. And across us, we have very